TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02674646

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation as indicated by the cancer diagnosis

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Radiotherapy
Description: Radiation as indicated by the cancer diagnosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle Acupuncture
Description: Needle Acupuncture according to Traditional Chinese Medicine (TCM)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Needle Acupuncture
Description: Needle Acupuncture according to Traditional Chinese Medicine (TCM)
Study: NCT01700400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT03298919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Video Games
Description: 12 weeks laboratory based exercise videogames

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Stationary bike and/or treadmill walking for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise videogames
Description: videogame console and active videogames

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Standard Exercise
Description: Personalized physical activity promotion materials
Study: NCT00155558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil, Leucovorin
Study: NCT01595854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: medium dose dabigatran

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: high dose ticagrelor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: high dose ticagrelor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: low dose dabigatran

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: medium dose dabigatran
Study: NCT03610958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epitomee Device
Description: A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety.
Study: NCT01309217

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The comparison group will receive usual care in accordance to how the hospital responds to current Joint Commission on Accreditation of Healthcare Organization's (JC) standards. JC standards require that a patient with a smoking history receives at least one of the following: advice to stop smoking, brochures or handouts on smoking cessation, a smoking cessation aid such as nicotine patch, gum, nasal spray, inhaler, lozenge, or bupropion SR, viewed a smoking cessation video.
Study: NCT02551679

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ACP-01
Description: Injection into lower extremity

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection into lower extremity
Study: NCT01521078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check Your Drinking University version
Description: The CYDU is an internet-based intervention that provides a personalized feedback summary which compares the participant's drinking to that of other university students. The CYDU is a modified version of the Check Your Drinking screener which has been validated in four separate randomized controlled trials. The primary modification of the CYDU is that the population norms used for comparison are those of university students (in the USA or Canada).
Study: NCT04352582

Intervention type: OTHER
Intervention: Survey
Description: Survey
Study: NCT02959658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimethyl fumarate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Manufactured to mimic Dimethyl Fumarate capsules
Study: NCT01312337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salvage iressa
Description: Iressa 250mg per day until progression
Study: NCT02523391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Tablet
Study: NCT01295086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 42, 51 or 60 mg/m² day 1 every 3. week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100 mg/m² day 1 every 3. week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1250 mg/² continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 8 mg/kg day 1, cycle 1. Following cycles 6 mg/kg every 3. week
Study: NCT00186823

Intervention type: DEVICE
Group type: OTHER
Intervention: Miltenyi Biotec CliniMACS
Description: A stem cell selection device.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem Cell Transplantation
Description: An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.

Intervention type: DRUG
Group type: OTHER
Intervention: TBI, systemic chemotherapy and antibodies as follows:
Description: Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3. Rituximab was provided prior to transplant for PTLPD prophylaxis. In addition to T cell depletion of the donor product, cyclosporine was administered for GVHD prophylaxis.
Study: NCT01997684

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonic Stenting with Elective Surgery
Description: After preparation of the distal colon with an enema, the colonoscope will be introduced up to the site of the obstruction. The colonic stent will be placed along a guide wire through the lesion under radiologic or endoscopic guidance. A colonic stent will be chosen which was at least 3 cm longer than the lesion (1.5 cm at either end). When the colonic stent did not cover the entire length of the lesion, a second overlapping stent will be placed.~If the colonic stenting failed (technical failure) or symptoms of colonic obstruction did not resolve within 3 days (clinical failure), patients were indicated for emergency surgery.~Candidates for elective surgery were preferably operated on 5-14 days after colonic stenting, and no later than 4 weeks.~Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emergency Surgery
Description: Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.
Study: NCT04659551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 90 mg/mq i.v. every 3 weeks for three cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamid 600 mg/mq i.v. every 3 weeks for three cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Triptorelin 3.75 mg i.m. every 4 weeks until surgery
Study: NCT00378092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Long-Acting Injection (RLAI)
Description: RLAI 25 mg to 50 mg will be administered, intramuscularly which will be tapered and discontinued over a period of up to 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Long-Acting Injection (RLAI)
Description: Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus for up to 24 months.
Study: NCT00785720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacyd PH_DETINBACK (Lactic Acid)
Study: NCT01081392

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS
Description: LPS 20mcg sd inhaled via nebulizer, 3 periods

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS
Description: LPS 20mcg sd inhaled via nebulizer, 3 periods
Study: NCT00929721

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: culture for Streptococcus pneumoniae Frequency-1

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chest X-ray
Description: image of the lungs to assess changes consistent with pneumonia Frequency-1

Intervention type: PROCEDURE
Group type: OTHER
Intervention: urine specimen
Description: assay for the presence of Streptococcus pneumoniae Binax and UAD

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nasopharyngeal swab
Description: culture for Streptococcus pneumoniae Frequency-1

Intervention type: PROCEDURE
Group type: OTHER
Intervention: sputum
Description: culture for Streptococcus pneumoniae Frequency-1
Study: NCT03414736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR425899
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR425899
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR425899
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study: NCT04659551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25 mg oral continuous daily dose until surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg flat dose i.v. every two weeks for 8 cycles
Study: NCT01513135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tat
Description: Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
Study: NCT02373995

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LAB4
Description: Additional treatment with the specific LAB4 probiotic preparation
Study: NCT01456741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBNA with ROSE
Description: The patients in this arm will undergo:~A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence with rapid on-site evaluation~B) if A will be negative transthoracic needle aspiration or surgical biopsy will be performed~C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography
Study: NCT01204658

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix Hexa (DTPa-HBV-IPV/Hib)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix Hexa (DTPa-HBV-IPV/Hib)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix Hexa (DTPa-HBV-IPV/Hib)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix Hexa (DTPa-HBV-IPV/Hib)
Description: Intramuscular injection
Study: NCT00786838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin will be administered as 1.3 mg/m2 3-hour intravenous infusion on Day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive 3-hour placebo intravenous infusion on Day 1.
Study: NCT06369675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOB015B
Description: Topical formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% SLS
Description: Positive control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Saline
Description: Negative control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOB015B vehicle
Description: Topical formulation
Study: NCT03013322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physostigmine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline
Study: NCT01839292

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncovered D-type stent insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double-layered ComVi stent insertion
Study: NCT04020484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Mindfulness Matter© (M3)
Description: Making Mindfulness Matter© (M3) is an interactive online parent and child program that incorporates mindful awareness, social-emotional learning skills, neuroscience, and positive psychology. This program was modelled after the school-based MindUP™ program for use in the community and augmented to integrate a parent component. M3E is a facilitator-led program that integrates attitudes, skills, and behaviours related to mindfulness and social-emotional learning (SEL). During the 8-week concurrent parent and child manualized program, parents learn the same core principles as children: how our brains work, stress and the brain, mindful breathing, mindful sensing, mindful movement, perspective taking, optimism, and gratitude/acts of kindness.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Making Mindfulness Matter© (M3)
Description: Making Mindfulness Matter© (M3) is an interactive online parent and child program that incorporates mindful awareness, social-emotional learning skills, neuroscience, and positive psychology. This program was modelled after the school-based MindUP™ program for use in the community and augmented to integrate a parent component. M3E is a facilitator-led program that integrates attitudes, skills, and behaviours related to mindfulness and social-emotional learning (SEL). During the 8-week concurrent parent and child manualized program, parents learn the same core principles as children: how our brains work, stress and the brain, mindful breathing, mindful sensing, mindful movement, perspective taking, optimism, and gratitude/acts of kindness.
Study: NCT01609803

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02410707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide arm
Description: Patients undergoing procedural sedation with propofol will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device before receiving propofol. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The loading dose of propofol will be administered immediately after nitrous oxide discontinuation. All sedations in this trial will use propofol 1.0 mg/Kg initial dose, with 0.5 mg/Kg doses titrated to deep sedation. Once the patient is deeply sedated, the procedure will begin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: If pulse oximetry declines to less than 92%, subject will be placed on nasal cannula with administration of 2 liter flow of oxygen and titrated in increments of 1 L flow to maintain pulse oximetry greater than 92%
Study: NCT03518099

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: Two tubes of 5ml of blood will be collected for Serum collection, 3 tubes of 5 ml of blood taken for plasma collection and 2 tubes of 7 ml of blood taken for DNA collection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: Two tubes of 5ml of blood will be collected for Serum collection, 3 tubes of 5 ml of blood taken for plasma collection and 2 tubes of 7 ml of blood taken for DNA collection
Study: NCT02998554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP640
Description: Instill 1 drop of SHP640 (PVP-I 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
Study: NCT01274442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anamnesis
Description: To update the anamnesis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: anamnesis
Description: To update the anamnesis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oral examination
Description: A brief clinical oral examination will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oral examination
Description: A brief clinical oral examination will be performed.
Study: NCT04028635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy plus VR-based body exposure
Description: Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: Usual CBT
Study: NCT02839369

Intervention type: OTHER
Intervention: walking under varies conditions
Description: The children were asked to walk an electronic mat, three cycles for each one of the different trials as comfortable regular speed, walking as fast and as slow as possible, walking on straight line etc
Study: NCT01456741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard EBNA
Description: The patients in this arm will undergo:~A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence.~B)if A will be negative transthoracic needle aspiration or surgical biopsy will be performed~C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography
Study: NCT02087176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD 1775 + antimitotic agent+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD1775 Placebo
Description: Placebo (to match dose) + antimitotic+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antimitotic Agent
Description: The antimitotic is a drug that stops cells from dividing. This leads to cell death. Because cancer cells divide faster than normal cells, they are more likely than normal cells to be affected by this drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antimitotic Agent
Description: The antimitotic is a drug that stops cells from dividing. This leads to cell death. Because cancer cells divide faster than normal cells, they are more likely than normal cells to be affected by this drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfiligrastim
Description: Pegfilgrastim is a man-made version of a protein called granulocyte-colony stimulating factor (G-CSF). This protein is made by cells in the body to stimulate the bone marrow to make more infection-fighting white blood cells.Pegfilgrastim is made by attaching filgrastim to a molecule called polyethylene glycol (PEG). This addition helps it stay in the body longer than filgrastim, which means it can be given less often.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pegfiligrastim
Description: Pegfilgrastim is a man-made version of a protein called granulocyte-colony stimulating factor (G-CSF). This protein is made by cells in the body to stimulate the bone marrow to make more infection-fighting white blood cells.Pegfilgrastim is made by attaching filgrastim to a molecule called polyethylene glycol (PEG). This addition helps it stay in the body longer than filgrastim, which means it can be given less often.
Study: NCT02839369

Intervention type: OTHER
Intervention: walking under varies conditions
Description: walking on electronic walkway under different conditions
Study: NCT01918579

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients will be tested by rapid POC CRP test
Description: Patient will be tested with CRP test. Treatment decisions including any antibiotics prescribed will be based on test results and clinical judgement. Treatment choices are not recommended/prescribed by the study protocol.
Study: NCT02244294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOMAX® capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Study: NCT03192046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Ankle Foot Orthosis (AFO)
Description: Custom AFOs in conjunction with a walking program, working up to walking 30 minutes 6 days a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized walking/exercise program
Description: standardized walking/exercise program without any brace or AFO
Study: NCT04577625

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri (L. reuteri)
Description: L.reuteri high or low dose with vitamin D3 compared to vitamin D3 only

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri (L. reuteri)
Description: L.reuteri high or low dose with vitamin D3 compared to vitamin D3 only
Study: NCT02439632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prulifloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prulifloxacin Placebo
Description: Placebo of prulifloxacin film-coated tablet without active components.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin Placebo
Description: Placebo of levofloxacin hydrochloride tablet without active components.
Study: NCT01674439

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supplementation of ADRC
Description: Isolation of ADRC from half of the aspirated fat and supplementation of the fat grafts with these cells

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Without supplementation of ADRC
Description: Standard fat graft preparation